


wherein X is O, S, SO, SO<sub>2</sub> or NR<sub>7</sub>;



n is 0 or 1;

R<sub>1</sub> and R<sub>2</sub> are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

R<sub>3</sub> is H or lower alkyl or a metal ion;

R<sub>4</sub> is H, halogen, CF<sub>3</sub>, hydroxy, alkyl, alkoxy, carboxyl, carboxyalkyl-, aminoalkyl, amino, alkanoylamino, aroylamino, cyano, alkoxyCON(R<sub>7d</sub>)-, R<sub>7f</sub>R<sub>7g</sub>NCO<sub>2</sub>-, R<sub>7f</sub>R<sub>7g</sub>NCO-, R<sub>7c</sub>SO<sub>2</sub>N(R<sub>7d</sub>)-, R<sub>7f</sub>R<sub>7g</sub>NSO<sub>2</sub>N(R<sub>7d</sub>)-, R<sub>7c</sub>OCO<sub>2</sub>- or R<sub>7c</sub>OCO;


R<sub>7</sub> is H, alkyl, aryl, alkanoyl, aroyl or alkoxycarbonyl, R<sub>7a</sub>SO<sub>2</sub>-, R<sub>7b</sub>R<sub>7c</sub>NSO<sub>2</sub>- or R<sub>7b</sub>R<sub>7c</sub>NCO-;

R<sub>7a</sub> and R<sub>7c</sub> are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroaryl;

R<sub>7b</sub> and R<sub>7c</sub>, and R<sub>7f</sub> and R<sub>7g</sub>, and R<sub>7d</sub> are the same or different and are independently selected from H, alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

R<sub>8</sub> is H or lower alkyl;


R<sub>9</sub> and R<sub>10</sub> are the same or different and are independently selected from H or alkyl; or where at least one of R<sub>9</sub> and R<sub>10</sub> is alkyl, R<sub>9</sub> and R<sub>10</sub> may be taken together with the carbon or carbons to which they are attached to form a 3 to 7 membered carbocyclic ring, which may include a spirocyclic ring;

and  represents a single bond or a double bond (which may be cis or trans);


or a pharmaceutically acceptable salt thereof (where R<sub>3</sub> is H), or an ester thereof, or a stereoisomer thereof;

and another therapeutic agent which is one or more hypolipidemic agents or lipid-lowering agents, or lipid agents, or lipid modulating agents, and/or one or more other types of therapeutic agents including antidiabetic agents, anti-obesity agents, antihypertensive agents, platelet aggregation inhibitors, anti-dementia agents, anti-Alzheimer's agents, anti-osteoporosis agents, and/or hormone replacement therapeutic agents, and/or other cardiovascular agents (including anti-anginal agents, anti-arrhythmic agents, anti-atherosclerosis agents, anti-inflammatory agents, anti-arthritis agents, anti-platelet agents, anti-heart failure agents), anti-cancer agents, anti-infective agents, hormone replacement agents, growth hormone secretagogues, selective androgen receptor modulators, and/or immunomodulatory agents.

46. (Amended) A method for treating cholesterol related diseases, diabetes and related diseases, cardiovascular diseases, cerebrovascular diseases, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a combination of a compound having the structure



wherein X is O, S, SO, SO<sub>2</sub> or NR<sub>7</sub>;



n is 0 or 1;

R<sub>1</sub> and R<sub>2</sub> are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

R<sub>3</sub> is H or lower alkyl or a metal ion;

R<sub>4</sub> is H, halogen, CF<sub>3</sub>, hydroxy, alkyl, alkoxy, carboxyl, carboxyalkyl-, aminoalkyl, amino, alkanoylamino, aroylamino, cyano, alkoxyCON(R<sub>7d</sub>)-, R<sub>7f</sub>R<sub>7g</sub>NCO<sub>2</sub>-, R<sub>7f</sub>R<sub>7g</sub>NCO-, R<sub>7c</sub>SO<sub>2</sub>N(R<sub>7d</sub>)-, R<sub>7f</sub>R<sub>7g</sub>NSO<sub>2</sub>N(R<sub>7d</sub>)-, R<sub>7c</sub>OCO<sub>2</sub>- or R<sub>7c</sub>OCO;